The HDAC2–MTA3 interaction induces nonsmall cell lung cancer cell migration and invasion by targeting c‐Myc and cyclin D1
Molecular Carcinogenesis · 2023
DOI: 10.1002/mc.23604 ↗At a glance
Journal article in Molecular Carcinogenesis, 2023. Written by Bin Wang and 7 co-authors. Institution: Shanghai Key Laboratory of Clinical Geriatric Medicine, Department of Thoracic Surgery, The Affiliated Huadong Hospital of Fudan University, Shanghai…. Major MEDLINE topics: Histone Deacetylase 2, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Proto-Oncogene Proteins c-myc. Cited 8 times so far (Crossref); 46 references. Funded by: National Natural Science Foundation of China, Shanghai Pujiang Talent Plan.
Abstract (original language)
Genome‐wide association studies have identified numerous single‐nucleotide polymorphisms (SNPs) associated with lung cancer; however, the functions of histone deacetylase 2 (HDAC2) rs13213007 and HDAC2 in nonsmall cell lung cancer (NSCLC) remain unclear. Here we identified HDAC2 rs13213007 as a risk SNP and showed that HDAC2 was upregulated in both peripheral blood mononuclear cells (PBMCs) and NSCLC tissues with the rs13213007 A/A genotype compared with those with the rs13213007 G/G or G/A genotype. Patient clinical data indicated strong associations between rs13213007 genotype and N classification. Immunohistochemical staining confirmed that higher expression of HDAC2 was associated with NSCLC progression. Furthermore, we generated 293T cells with the rs13213007 A/A genotype using CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 gene editing. Chromatin immunoprecipitation sequencing followed by motif analysis showed that HDAC2 can bind to c‐Myc in rs13213007 A/A 293T cells. Cell Counting Kit‐8, colony formation, wound‐healing, and Transwell assays revealed that HDAC2 upregulates c‐Myc and cyclin D1 expression and promotes NSCLC cell proliferation, migration, and invasion. Co‐immunoprecipitation, quantitative reverse transcription–polymerase chain reaction, and western blot analysis assays showed that MTA3 interacts with HDAC2, decreases HDAC2 expression, and rescues the migration and invasion abilities of NSCLC cells. Taken together, these findings identify HDAC2 as a potential therapeutic biomarker in NSCLC.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Shanghai Key Laboratory of Clinical Geriatric Medicine, Department of Thoracic Surgery, The Affiliated Huadong Hospital of Fudan University, Shanghai, China.
- Department of Respiration, The Affiliated Zhongshan Hospital of Fudan University, Shanghai, China.
ORCID profiles: Xiao-Yong Shen, Wen Gao
Funding
- National Natural Science Foundation of China
- Shanghai Pujiang Talent Plan
Cite
APA
Wang, B., Shen, X. Y., Pan, L. Y., Li, Z., Chen, C. J., Yao, Y. S., Tang, D. F., & Gao, W. (2023). The HDAC2–MTA3 interaction induces nonsmall cell lung cancer cell migration and invasion by targeting c‐Myc and cyclin D1. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23604
Vancouver
Wang B, Shen XY, Pan LY, Li Z, Chen CJ, Yao YS, et al. The HDAC2–MTA3 interaction induces nonsmall cell lung cancer cell migration and invasion by targeting c‐Myc and cyclin D1. Molecular Carcinogenesis. 2023. doi:10.1002/mc.23604
BibTeX
@article{Wang2023,
author = {Wang, Bin and Shen, Xiao-Yong and Pan, Lin-Yue and Li, Zheng and Chen, Chun-Ji and Yao, Yuan-Shan and Tang, Dong-Fang and Gao, Wen},
title = {The HDAC2–MTA3 interaction induces nonsmall cell lung cancer cell migration and invasion by targeting c‐Myc and cyclin D1},
journal = {Molecular Carcinogenesis},
year = {2023},
doi = {10.1002/mc.23604}
}
EUVIMED